EP1513825A4 - Antituberkulöses arzneimittel: zusammensetzungen und verfahren - Google Patents

Antituberkulöses arzneimittel: zusammensetzungen und verfahren

Info

Publication number
EP1513825A4
EP1513825A4 EP03729047A EP03729047A EP1513825A4 EP 1513825 A4 EP1513825 A4 EP 1513825A4 EP 03729047 A EP03729047 A EP 03729047A EP 03729047 A EP03729047 A EP 03729047A EP 1513825 A4 EP1513825 A4 EP 1513825A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
tuberculous
drug
tuberculous drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP03729047A
Other languages
English (en)
French (fr)
Other versions
EP1513825B1 (de
EP1513825A2 (de
Inventor
Marina Nikolaevna Protopopova
Richard Edward Lee
Richard Allan Slayden
Iii Clifton E Barry
Leo Einck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sequella Inc
US Department of Health and Human Services
Original Assignee
Sequella Inc
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/147,587 external-priority patent/US6951961B2/en
Application filed by Sequella Inc, US Department of Health and Human Services filed Critical Sequella Inc
Publication of EP1513825A2 publication Critical patent/EP1513825A2/de
Publication of EP1513825A4 publication Critical patent/EP1513825A4/de
Application granted granted Critical
Publication of EP1513825B1 publication Critical patent/EP1513825B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/35—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/14—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic the nitrogen atom of the amino group being further bound to hydrocarbon groups substituted by amino groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C215/30—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
    • C07C215/58—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C07C215/60—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
    • C07C217/10—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/46—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms
    • C07C323/47—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms to oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP03729047.5A 2002-05-17 2003-05-19 Antituberkulöses arzneimittel: zusammensetzungen und verfahren Expired - Lifetime EP1513825B1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38122002P 2002-05-17 2002-05-17
US381220P 2002-05-17
US10/147,587 US6951961B2 (en) 2002-05-17 2002-05-17 Methods of use and compositions for the diagnosis and treatment of infectious disease
US147587 2002-05-17
PCT/US2003/015927 WO2003096989A2 (en) 2002-05-17 2003-05-19 Anti tubercular drug: compositions and methods

Publications (3)

Publication Number Publication Date
EP1513825A2 EP1513825A2 (de) 2005-03-16
EP1513825A4 true EP1513825A4 (de) 2011-01-05
EP1513825B1 EP1513825B1 (de) 2016-10-05

Family

ID=29552723

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03729047.5A Expired - Lifetime EP1513825B1 (de) 2002-05-17 2003-05-19 Antituberkulöses arzneimittel: zusammensetzungen und verfahren

Country Status (9)

Country Link
US (4) US20040033986A1 (de)
EP (1) EP1513825B1 (de)
JP (1) JP4667862B2 (de)
CN (1) CN1665801B (de)
AU (1) AU2003233610B2 (de)
CA (1) CA2485592C (de)
EA (2) EA020307B1 (de)
WO (1) WO2003096989A2 (de)
ZA (1) ZA200409169B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3433986A (en) * 1966-06-13 1969-03-18 Reda Pump Co Oil filled elongated submergible electric motor
US7338969B2 (en) * 2002-03-08 2008-03-04 Quonova, Llc Modulation of pathogenicity
US7335779B2 (en) * 2002-03-08 2008-02-26 Quonova, Llc Modulation of pathogenicity
US7456222B2 (en) * 2002-05-17 2008-11-25 Sequella, Inc. Anti tubercular drug: compositions and methods
US7652039B2 (en) * 2002-05-17 2010-01-26 Sequella, Inc. Methods of use and compositions for the diagnosis and treatment of infectious disease
US20040033986A1 (en) * 2002-05-17 2004-02-19 Protopopova Marina Nikolaevna Anti tubercular drug: compositions and methods
US20070196340A1 (en) * 2003-05-06 2007-08-23 Aldo Ammendola Modulation of Pathogenicity
EP1670314A4 (de) * 2003-09-05 2009-02-25 Sequella Inc Verfahren und zusammensetzungen enthaltend diamine als neue therapeutika für tuberkulose
CN1865259B (zh) * 2005-05-19 2010-09-29 北京德众万全医药科技有限公司 一种哌啶衍生物的制备方法
US20090281054A1 (en) * 2008-05-06 2009-11-12 Venkata Reddy Compositions and methods comprising capuramycin analogues
CN101468958B (zh) * 2008-08-26 2012-05-02 上海阳帆医药科技有限公司 乙二胺衍生物
WO2010043721A1 (en) 2008-10-17 2010-04-22 Oryzon Genomics, S.A. Oxidase inhibitors and their use
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
US8859555B2 (en) 2009-09-25 2014-10-14 Oryzon Genomics S.A. Lysine Specific Demethylase-1 inhibitors and their use
EP2486002B1 (de) 2009-10-09 2019-03-27 Oryzon Genomics, S.A. Substituierte heteroaryl- und arylcyclopropylaminacetamide und ihre verwendung
WO2011106573A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
US9616058B2 (en) 2010-02-24 2017-04-11 Oryzon Genomics, S.A. Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
MX2012012111A (es) 2010-04-19 2013-05-30 Oryzon Genomics Sa Inhibidores de demetilasa-1 especifica de lisina y su uso.
WO2012013727A1 (en) 2010-07-29 2012-02-02 Oryzon Genomics S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
SI2598482T1 (sl) 2010-07-29 2018-09-28 Oryzon Genomics, S.A. Inhibitorji demetilaze lsd1 na osnovi arilciklopropilamina in njihova medicinska uporaba
WO2012045883A1 (en) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
KR20130122735A (ko) * 2010-10-27 2013-11-08 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. 생물학적 특성이 부여된 다이테르페노이드 유도체
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
WO2012107498A1 (en) 2011-02-08 2012-08-16 Oryzon Genomics S.A. Lysine demethylase inhibitors for myeloproliferative disorders
PL2678307T3 (pl) * 2011-02-23 2018-11-30 Université D'aix-Marseille Zastosowanie pochodnych poliaminoizoprenylu w leczeniu antybiotykami lub środkami antyseptycznymi
EP2741741A2 (de) * 2011-05-19 2014-06-18 Oryzon Genomics, S.A. Lysindemethylaseinhibitoren zur entzündungserkrankungen oder -zustände
CN107266345B (zh) 2011-10-20 2021-08-17 奥瑞泽恩基因组学股份有限公司 作为lsd1抑制剂的(杂)芳基环丙胺化合物
RS58475B1 (sr) 2011-10-20 2019-04-30 Oryzon Genomics Sa Jedinjenja (hetero)aril ciklopropilamina kao lsd1 inhibitori
WO2013184202A1 (en) 2012-06-08 2013-12-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Fbxo3 inhibitors
WO2015035234A2 (en) * 2013-09-06 2015-03-12 The Board Of Trustees Of The University Of Illinois Anti-microbial compounds and compositions
WO2015089087A1 (en) 2013-12-09 2015-06-18 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Compositions and methods for treating respiratory injury or disease
SG11201810861PA (en) 2014-12-10 2019-01-30 Univ Pittsburgh Commonwealth Sys Higher Education Compositions and methods for treating diseases and conditions
RU2649406C1 (ru) * 2017-09-21 2018-04-03 Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) 3-n-замещенные борнилпропионаты, используемые в качестве ингибиторов вируса марбург
RU2687254C1 (ru) * 2018-10-03 2019-05-08 Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) N-гетероциклические производные борниламина в качестве ингибиторов ортопоксвирусов
WO2020135569A1 (zh) * 2018-12-26 2020-07-02 中国人民解放军军事科学院军事医学研究院 乙二胺类化合物及其用途
CN111870594B (zh) * 2020-08-27 2022-03-22 首都医科大学附属北京胸科医院 苯乙肼在制备抗偶发分枝杆菌感染的药物中的应用

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR913169A (fr) * 1941-12-10 1946-08-30 Rhone Poulenc Sa Procédé de préparation de diamines arylaliphatiques
US2483434A (en) * 1946-04-08 1949-10-04 Parke Davis & Co Disubstituted amino-alkyl benzhydryl amines
US2627491A (en) * 1950-07-15 1953-02-03 Wyeth Corp Penicillin salts of substituted alkylene diamines
US2767161A (en) * 1956-07-02 1956-10-16 Bristol Lab Inc Dehydroabietyl-ethylenediamine
US2876236A (en) * 1952-08-26 1959-03-03 American Home Prod Heterocyclic diamines and salts thereof
GB898928A (en) * 1960-03-14 1962-06-14 American Cyanamid Co Antitubercular compositions comprising substituted ethylenediamines
GB919177A (en) * 1960-09-14 1963-02-20 Ici Ltd Substituted ethylenediamines
US3463861A (en) * 1961-02-07 1969-08-26 American Cyanamid Co Compositions and method of treating mycobacterium tuberculosis with 2,2'-(ethylenediimino)-di-1-butanols
US3876702A (en) * 1968-04-26 1975-04-08 Rudolf Theodor Petersen N,n-bis-(diphenylalkyl)-alkylendiamine and their salts
US4204998A (en) * 1974-03-28 1980-05-27 Siegfried Aktiengesellschaft N-Amino indole derivatives having pharmacological activity
DE3213067A1 (de) * 1982-04-07 1983-10-20 Chem. pharmaz. Fabrik Dr. Hermann Thiemann GmbH, 4670 Lünen N,n-dialkyl-n'-(omega),(omega)-diphenylalkyl-1,2-aethandiamin-verbindungen, verfahren zu ihrer herstellung und solche verbindungen enthaltende arzneimittel
EP0569592A1 (de) * 1991-08-23 1993-11-18 Otsuka Pharmaceutical Co., Ltd. Carbostyrilderivate als inhibitoren der blutplättchen agglutination
US5380947A (en) * 1992-09-11 1995-01-10 Mobil Oil Corporation Diamondoid-containing amines
WO1998005332A1 (en) * 1996-08-01 1998-02-12 Isis Pharmaceuticals, Inc. Novel heterocycle compositions
WO2001092232A1 (en) * 2000-05-27 2001-12-06 Ufc Ltd. 4-aminoquinolines as antiinfective agents

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US526391A (en) 1894-09-25 Harry c
US2709169A (en) * 1955-05-24 X c chs
DE831249C (de) * 1948-02-09 1952-02-11 Ciba A G Verfahren zur Herstellung heterocyclisch substituierter Diaminochinazoline
NL70218C (de) * 1948-02-09
FR1067944A (fr) 1951-08-21 1954-06-21 Bayer Ag Production de 4-aminotoluènes substitués
DE1251770B (de) * 1960-06-02 1967-10-12 American Cyanamid Company, New York NY (V St A) Verfahren zur Herstellung von aliphatischen Hydroxydiammen und de ren Saureadditionssalzen
AT243774B (de) 1961-02-07 1965-11-25 American Cyanamid Co Verfahren zur Herstellung von neuen Hydroxydiaminen
NL126233C (de) * 1963-02-18
NL6410363A (de) * 1964-09-05 1966-03-07
GB1157143A (en) 1966-06-21 1969-07-02 Du Pont Adamantane Derivatives
US3553257A (en) * 1966-09-16 1971-01-05 American Cyanamid Co Preparation of d-2-amino-1-butanol salts
GB1198923A (en) * 1968-04-18 1970-07-15 Zoja Lab Chim Farm Process for the Preparation of the Dextrorotatory 2, 2', (Ethylenediimino)-di-1-butanoldihydrochloride
DE1768297B1 (de) * 1968-04-26 1971-12-16 Beiersdorf Ag Substituierte Alkylendiamine und deren Salze
DE1768612A1 (de) * 1968-06-06 1971-11-18 Zoja Lab Chim Farm Verfahren zur Herstellung von sehr reinem,pharmazeutisch geeignetem rechtsdrehenden 2,2'-(AEthylendiimin)-di-1-butanoldihydrochlorid
US3682922A (en) * 1969-01-16 1972-08-08 Searle & Co N-acyl-n-{8 (n{40 ,n{40 -disubstituted amino)-alkyl{9 -1-adamantylmethylamines
BR6915423D0 (pt) 1969-03-21 1973-06-14 Farmaceutici Italia Processo para preparacao de etambutol
ES369952A1 (es) * 1969-07-28 1971-07-16 Ferrer Labor Procedimiento de fabricacion de un nuevo derivado dihidra- cinico de accion antituberculosa.
US3629333A (en) * 1969-08-28 1971-12-21 Du Pont Polymethylenebis admantane amines
US3789073A (en) * 1970-04-22 1974-01-29 Squibb & Sons Inc Adamantylalkylaminoalkyl benzamides
US3716040A (en) * 1970-08-21 1973-02-13 I Herpin Fuel additive inductor for internal combustion engine
US3769347A (en) * 1971-02-11 1973-10-30 American Cyanamid Co Production of d,d'-2,2'-(ethylenediimino) di-1-butanol hydrochloride
US3878201A (en) * 1971-04-05 1975-04-15 American Cyanamid Co 1,5-Bis substituted-1,4-pentadien-3-one substituted amidinohydrazone salts and method of preparing the same
YU35869B (en) * 1971-12-30 1981-08-31 Farmaceutici Italia Process for preparing (+)-2,2-(1,2-ethylene-diimino)-dibutane-1-ole
YU35103B (en) * 1972-06-09 1980-09-25 Pliva Zagreb Process for preparing d-n,n-bis-(1-hydroxymethylpropyl)-ethylenediamine
USRE29358E (en) 1973-03-01 1977-08-16 American Cyanamid Company 1,5-Bis substituted-1,4-pentadien-3-one substituted amidino hydrazone salts and method of preparing the same
US3855300A (en) * 1973-09-05 1974-12-17 Sankyo Chem Ind Ltd Process for the production of 2-amino-1-butanol
JPS5318006B2 (de) * 1973-09-28 1978-06-13
GB1438125A (en) * 1973-11-29 1976-06-03 Lepetit Spa Preparation of a-aminoalcohols
US3931152A (en) 1974-01-29 1976-01-06 American Cyanamid Company 2-(1,3-Diazacycloalkenyl)-2-hydrazones of substituted chalcones
US3944616A (en) 1974-10-29 1976-03-16 American Cyanamid Company Purification of d,d'-2,2'(ethylenediimino)di-1-butanol dihydrochloride
US4006234A (en) 1974-12-18 1977-02-01 American Cyanamid Company Substituted 2-benzofuranyl propenones as anti-tubercular agents
US3931157A (en) 1974-12-18 1976-01-06 American Cyanamid Company Substituted 2-benzofuranyl propenones and method of preparation
US4150030A (en) * 1975-12-22 1979-04-17 American Cyanamid Company 3-Acyl-4-ethyl-2-oxazolones and oxazolidinones
US3944608A (en) * 1976-02-20 1976-03-16 American Cyanamid Company Synthesis of N-[1-(chloromethyl)propyl]acetamide
SU805605A1 (ru) 1979-10-12 1981-09-30 Предприятие П/Я В-2343 N-(1-адамантилметил-)-2-хлорацетамид как полупродукт дл синтеза гидрогалогенидов N-(2-оксиэтил)-аминоалкильных производных 1-адамантилметиламина
SU803348A1 (ru) 1979-10-12 1981-09-30 Предприятие П/Я В-2343 Оксиэтиламмониевые производные адамантана,обладающие антивирусной активностью
US4262122A (en) 1980-02-19 1981-04-14 American Cyanamid Company Preparation of 5,5-dimethyl-2-hydrazino-1,4,5,6-tetrahydro-pyrimidine hydrohalide
CA1157774A (en) * 1980-07-30 1983-11-29 Anthony Cerami Method for the reduction of mucin viscosity
KR820002345B1 (ko) * 1981-07-07 1982-12-23 한국과학기술원 에탐부톨술폰산 유도체의 제조방법
US4457931A (en) * 1982-09-27 1984-07-03 Selvi & C. S.P.A. Piperazine derivatives with anticholinergic and/or antihistaminic activity
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
DE3916417A1 (de) * 1989-05-19 1990-11-22 Saarstickstoff Fatol Gmbh Kombinationspraeparate enthaltend rifampicin und thioacetazon sowie gegebenenfalls isonicotinsaeurehydrazid als aktive wirkstoffe
US4985560A (en) 1990-01-12 1991-01-15 American Home Products Corporation Pyridazino(4,5-b)indolizines
RU2145233C1 (ru) * 1990-07-02 2000-02-10 Дзе Аризона Борд оф Риджентс Неупорядоченная библиотека пептидов, способ ее получения и способ идентификации пептида, синтезированного твердофазным синтезом
DE69129907T2 (de) * 1990-11-30 1998-12-10 Idemitsu Kosan Co. Ltd., Tokio/Tokyo Organische elektroluminszente vorrichtung
FI942187A7 (fi) 1991-11-12 1994-05-11 Pfizer Asyklisiä etyleenidiamiinijohdannaisia aine P-reseptoriantagonisteina
US6300061B1 (en) * 1992-02-07 2001-10-09 Albert Einstein College Of Medicine Of Yeshiva University Mycobacterial species-specific reporter mycobacteriophages
ES2160597T3 (es) * 1992-03-06 2001-11-16 Lica Pharmaceuticals As Tratamiento y profilaxis de enfermedades producidas por parasitos o bacterias.
US5576355A (en) 1993-06-04 1996-11-19 Mobil Oil Corp. Diamondoid derivatives for pharmaceutical use
US5439891A (en) * 1993-10-29 1995-08-08 Kapil; Randhir S. Process for preparation of pharmaceutical composition with enhanced activity for treatment of tuberculosis and leprosy
ATE206421T1 (de) * 1995-03-15 2001-10-15 Aventis Pharma Inc Heterocyclisch substituierte piperazonderivate als tachykinin rezeptor antagonisten
US5922282A (en) * 1995-06-07 1999-07-13 Ledley; Robert S. Super fast tuberculosis diagnosis and sensitivity testing method
WO1999051213A2 (en) * 1998-04-03 1999-10-14 Theodore Toney Ilenchuk The use of polyamines in the treatment of dermatological symptoms
WO2000002892A1 (fr) * 1998-07-09 2000-01-20 Sankyo Company, Limited Nouveaux composes antibacteriens
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
US6392012B1 (en) * 1998-12-23 2002-05-21 Advanced Medicine, Inc. Glycopeptide derivatives and pharmaceutical compositions containing the same
TWI245047B (en) * 1999-08-20 2005-12-11 Sankyo Co Novel A-500359 derivatives
KR20020088406A (ko) * 1999-09-17 2002-11-27 애보트 게엠베하 운트 콤파니 카게 치료제로서의 피라졸로피리미딘
WO2001068042A1 (en) * 2000-03-17 2001-09-20 Novozymes A/S Method for dyeing dry hair
EP1568692B1 (de) 2000-05-31 2010-09-15 Santen Pharmaceutical Co., Ltd. (Pyridinyl)alkyl-Amide oder -Harnstoffe als TNF-alpha Bildung Inhibitoren
RU2168986C1 (ru) * 2000-08-03 2001-06-20 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Фармацевтическая композиция, обладающая противотуберкулезным действием
WO2003008379A1 (en) * 2001-06-08 2003-01-30 Mitsubishi Chemical Corporation Azasugar compounds
AU2002349621A1 (en) * 2001-11-30 2003-06-10 Santen Pharmaceutical Co., Ltd. Angiogenesis inhibitor
AU2003202115A1 (en) 2002-02-12 2003-09-04 Pfizer Inc. Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh)
ES2334990T3 (es) * 2002-02-14 2010-03-18 Pharmacia Corporation Piridinonas sustituidas como moduladores de p38 map quinasa.
US20040033986A1 (en) 2002-05-17 2004-02-19 Protopopova Marina Nikolaevna Anti tubercular drug: compositions and methods
US6951961B2 (en) * 2002-05-17 2005-10-04 Marina Nikolaevna Protopopova Methods of use and compositions for the diagnosis and treatment of infectious disease
US7456222B2 (en) * 2002-05-17 2008-11-25 Sequella, Inc. Anti tubercular drug: compositions and methods
EP1670314A4 (de) * 2003-09-05 2009-02-25 Sequella Inc Verfahren und zusammensetzungen enthaltend diamine als neue therapeutika für tuberkulose

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR913169A (fr) * 1941-12-10 1946-08-30 Rhone Poulenc Sa Procédé de préparation de diamines arylaliphatiques
US2483434A (en) * 1946-04-08 1949-10-04 Parke Davis & Co Disubstituted amino-alkyl benzhydryl amines
US2627491A (en) * 1950-07-15 1953-02-03 Wyeth Corp Penicillin salts of substituted alkylene diamines
US2876236A (en) * 1952-08-26 1959-03-03 American Home Prod Heterocyclic diamines and salts thereof
US2767161A (en) * 1956-07-02 1956-10-16 Bristol Lab Inc Dehydroabietyl-ethylenediamine
GB898928A (en) * 1960-03-14 1962-06-14 American Cyanamid Co Antitubercular compositions comprising substituted ethylenediamines
GB919177A (en) * 1960-09-14 1963-02-20 Ici Ltd Substituted ethylenediamines
US3463861A (en) * 1961-02-07 1969-08-26 American Cyanamid Co Compositions and method of treating mycobacterium tuberculosis with 2,2'-(ethylenediimino)-di-1-butanols
US3876702A (en) * 1968-04-26 1975-04-08 Rudolf Theodor Petersen N,n-bis-(diphenylalkyl)-alkylendiamine and their salts
US4204998A (en) * 1974-03-28 1980-05-27 Siegfried Aktiengesellschaft N-Amino indole derivatives having pharmacological activity
DE3213067A1 (de) * 1982-04-07 1983-10-20 Chem. pharmaz. Fabrik Dr. Hermann Thiemann GmbH, 4670 Lünen N,n-dialkyl-n'-(omega),(omega)-diphenylalkyl-1,2-aethandiamin-verbindungen, verfahren zu ihrer herstellung und solche verbindungen enthaltende arzneimittel
EP0569592A1 (de) * 1991-08-23 1993-11-18 Otsuka Pharmaceutical Co., Ltd. Carbostyrilderivate als inhibitoren der blutplättchen agglutination
US5380947A (en) * 1992-09-11 1995-01-10 Mobil Oil Corporation Diamondoid-containing amines
WO1998005332A1 (en) * 1996-08-01 1998-02-12 Isis Pharmaceuticals, Inc. Novel heterocycle compositions
WO2001092232A1 (en) * 2000-05-27 2001-12-06 Ufc Ltd. 4-aminoquinolines as antiinfective agents

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002609614, retrieved from STN Database accession no. 1983:197635 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002609808, retrieved from STN Database accession no. 1971:431808 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002610202, retrieved from STN Database accession no. 1962:419505 *
E. FREERKSEN ET AL, ARZNEIMITEL-FORSCHUNG, no. 12, 1962, pages 259 - 260 *
L.M. WERBEL ET AL, J. MED. CHEM, vol. 6, no. 6, 1963, pages 637 - 646, XP002609807 *
M.R. PATEL ET AL, INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY, vol. 9, no. 1, 1971, pages 117 - 119 *
P. BERTHELOT ET AL, FARMACO, EDIZIONE SCIENTIFICA, vol. 38, no. 2, 1983, pages 73 - 80 *
P.E. ALDRICH ET AL, J. MED. CHEM., vol. 14, no. 6, 1971, pages 535 - 543, XP002609615 *
R.E. LEE ET AL, J. COMB. CHEM., vol. 5, no. 2, 2003, pages 172 - 187, XP002978728 *
S. LEE ET AL, JOURNAL OF ORGANIC CHEMISTRY, vol. 66, 18 May 2001 (2001-05-18), pages 3402 - 3415, XP001038253, ISSN: 0022-3263, DOI: 10.1021/JO005761Z *
See also references of WO03096989A2 *
W. MEINDL, ARCHIV DER PHARMAZIE (WEINHEIM), vol. 321, no. 8, 1988, pages 473 - 476, XP002527572 *

Also Published As

Publication number Publication date
CN1665801A (zh) 2005-09-07
EP1513825B1 (de) 2016-10-05
WO2003096989A3 (en) 2004-09-16
EA200401522A1 (ru) 2005-10-27
WO2003096989A2 (en) 2003-11-27
US20110118307A1 (en) 2011-05-19
CA2485592A1 (en) 2003-11-27
US20040033986A1 (en) 2004-02-19
CN1665801B (zh) 2011-05-11
JP2005526129A (ja) 2005-09-02
US20060020041A1 (en) 2006-01-26
CA2485592C (en) 2013-07-16
EA201000643A1 (ru) 2010-08-30
EA013965B1 (ru) 2010-08-30
EA020307B1 (ru) 2014-10-30
US7842729B2 (en) 2010-11-30
JP4667862B2 (ja) 2011-04-13
AU2003233610B2 (en) 2010-06-17
EP1513825A2 (de) 2005-03-16
US8268894B2 (en) 2012-09-18
ZA200409169B (en) 2005-11-30
US20040019117A1 (en) 2004-01-29
AU2003233610A1 (en) 2003-12-02

Similar Documents

Publication Publication Date Title
LUC00127I2 (fr) Dacomitinib et ses derives pharmaceutiquement accepatbles ( vizimpro )
HUE040046T2 (hu) Gyógyszerészeti készítmények és hatóanyagok beadására szolgáló eljárások
EP1765379A4 (de) Pharmazeutische ko-kristallzusammensetzungen und relevante anwendungsverfahren
PT1501534E (pt) Formulacoes farmaceuticas
EP1701725A4 (de) Verfahren und zusammensetzungen
DK1545662T3 (da) Lægemiddelindgivelsessystem
KR20050009999A (ko) 약제학적 제제
EP1603593A4 (de) Pharmazeutische zusammensetzung
EP1477403A4 (de) Arzneimittelversorgung
DE602004017700D1 (de) Transmukosen verabreichung
DE60308372D1 (de) Dosierungsverabreichungsvorrichtung
EP1799865A4 (de) Verfahren für die verabreichung von iloperidone
DK1425019T3 (da) Farmaceutisk sammensætning omfattende et androgen
IS7571A (is) Ný lífeðlisfræðilega virk efni
DK1587478T3 (da) Farmaceutisk sammensætning
FR2873691B1 (fr) Derives d'amino-piperidine, leur preparation et leur application en therapeutique
DE60312049D1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
PT1467724E (pt) Composicao farmaceutica orodispersavel de agomelatina
NO20055652D0 (no) Laktatinneholdende farmasoytisk preparat og anvendelse av dette
NO20052952D0 (no) Farmasoytisk sammensetning som innbefatter mikropartikler
IL170313A (en) Diarylcycloalkyl derivatives and pharmaceutical compositions comprising them
NO20055173D0 (no) Farmasoytisk kombinasjonsblanding omfattende modafinil og et annet legemiddel
PL361518A1 (pl) Zastosowanie substancji oraz kompozycja farmaceutyczna
NO20043576L (no) Pharmaceutical formulation comprising melatonin
DK1682144T3 (da) Smagsstofholdige lægemiddelformuleringer med forbedrede farmaceutiske egenskaber

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041217

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RIN1 Information on inventor provided before grant (corrected)

Inventor name: EINCK, LEO

Inventor name: SLAYDEN, RICHARD ALLAN

Inventor name: LEE, RICHARD EDWARD

Inventor name: PROTOPOPOVA, MARINA NIKOLAEVNA

Inventor name: BARRY III, CLIFTON E.

DAX Request for extension of the european patent (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: BARRY III, CLIFTON E.

Inventor name: SLAYDEN, RICHARD ALLAN

Inventor name: PROTOPOPOVA, MARINA NIKOLAEVNA

Inventor name: LEE, RICHARD EDWARD

Inventor name: EINCK, LEO

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 211/46 20060101ALI20101125BHEP

Ipc: C07C 215/30 20060101ALI20101125BHEP

Ipc: C07C 211/27 20060101AFI20101125BHEP

Ipc: A61K 31/445 20060101ALI20101125BHEP

Ipc: A61K 31/40 20060101ALI20101125BHEP

Ipc: A61K 31/133 20060101ALI20101125BHEP

Ipc: A61K 31/132 20060101ALI20101125BHEP

Ipc: C07C 217/62 20060101ALI20101125BHEP

Ipc: C07C 217/08 20060101ALI20101125BHEP

Ipc: C07C 211/29 20060101ALI20101125BHEP

Ipc: C07C 211/34 20060101ALI20101125BHEP

Ipc: C07C 211/35 20060101ALI20101125BHEP

Ipc: C07C 211/42 20060101ALI20101125BHEP

Ipc: C07C 215/14 20060101ALI20101125BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20101203

17Q First examination report despatched

Effective date: 20110228

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150630

INTG Intention to grant announced

Effective date: 20150715

INTG Intention to grant announced

Effective date: 20160104

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 834491

Country of ref document: AT

Kind code of ref document: T

Effective date: 20161015

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 60349459

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20161005

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 834491

Country of ref document: AT

Kind code of ref document: T

Effective date: 20161005

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161005

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170106

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161005

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161005

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161005

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170206

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161005

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161005

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 60349459

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161005

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161005

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161005

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161005

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161005

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170105

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170531

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161005

26N No opposition filed

Effective date: 20170706

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161005

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161005

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20171121

Year of fee payment: 15

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170531

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170519

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170519

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20030519

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161005

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161005

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20211116

Year of fee payment: 19

Ref country code: DE

Payment date: 20211118

Year of fee payment: 19

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60349459

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20220519

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220519

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221201